Trials / Recruiting
RecruitingNCT07286656
A Study of GensSci098 in Subjects With Graves' Disease
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Subcutaneous Dose of GenSci098 in Patients With Graves' Disease
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (estimated)
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the safety and tolerability of single ascending subcutaneous doses of GenSci098 in patients with Graves' Disease
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GenSci098 | * Administration: Only one dose of GenSci098 will be given. * Route of Administration: Subcutaneous (injected under the skin). * Dose Levels: • Dose 1 • Dose 2• Dose 3• Dose 4 |
Timeline
- Start date
- 2025-11-21
- Primary completion
- 2026-10-28
- Completion
- 2027-03-18
- First posted
- 2025-12-16
- Last updated
- 2026-02-17
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07286656. Inclusion in this directory is not an endorsement.